NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Abiraterone市場分析(2021年∼2025年)

Investigation Report on China's Abiraterone Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008259
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Abiraterone市場分析(2021年∼2025年) Investigation Report on China's Abiraterone Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

Abiraterone,主要是作為前列腺癌症治療所使用的CYP17抑制劑,由Johnson & Johnson的子公司的 Janssen-Cilag International NV 開發。Abiraterone2015年進入中國市場,2020年時,Janssen-Cilag International NV ,加上Chengdu Suncadia Medicine,Chia Tai Tianqing Pharmaceutical Group,Jiangxi Shanxiang Pharmaceutical,Qilu Pharmaceutical等也進行製造。

從2016年到2019年,在中國的Abiraterone的銷售額有增加趨勢。到2017年Abiraterone的藥價下降,適用中國的國民醫療保險。Abiraterone的2019年的銷售量是5億6,684萬人民幣,與2016年比較增加到30倍以上。2020年由於新型冠狀病毒感染疾病(COVID-19)的發生對醫療產生大幅影響,銷售額多少減少。從2016年到2020年中國的Abiraterone的銷售量記錄140.7%的年複合成長率。

本報告提供中國的Abiraterone市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售額數,價格趨勢,市場預測,市場成長要素,市場機會,課題等彙整資料。

目錄

第1章 Abiraterone概要

  • Abiraterone的適應症
  • 中國的Abiraterone的開發
  • 中國的Abiraterone的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)對銷售的影響

第2章 中國的Abiraterone的銷售趨勢(2016年∼2020年)

  • Abiraterone的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Abiraterone的銷售額數
    • 銷售額數:全體
    • 銷售額數:各地區
  • Abiraterone的銷售趨勢:各劑型
    • 平板電腦
    • 其他劑型

第3章 中國的主要Abiraterone製造企業(2016年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售額數
  • Janssen-Cilag International NV(BE)
    • 企業概要
    • 中國的zaitiga/ZYTIGA的銷售額
  • Chengdu Suncadia Medicine Co., Ltd.
    • 企業概要
    • 中國的AISENTE的銷售額
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 企業概要
    • 中國的QINGKESHU的銷售額
  • Jiangxi Shanxiang Pharmaceutical Co., Ltd.
    • 企業概要
    • 中國的Abiraterone的銷售額
  • Qilu Pharmaceutical Co., Ltd.
    • 企業概要
    • 中國的ZHUORONG的銷售額

第4章 中國的Abiraterone的價格(2020年∼2021年)

  • Janssen-Cilag International NV(BE) (zaitiga/ZYTIGA)
  • Chengdu Suncadia Medicine Co., Ltd. (Aisente)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(Qingkeshu)
  • Jiangxi Shanxiang Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.(Zhuorong)

第5章 中國的Abiraterone市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105494

Abiraterone is a CYP17 inhibitor, which is mainly clinically used to treat prostate cancer patients. Its product ZYTIGA was developed by Janssen-Cilag International NV(a subsidiary of Johnson & Johnson). In 2015, Abiraterone entered the Chinese market. As of 2020, in addition to Janssen-Cilag International NV, the main manufacturers of Abiraterone in China are Chengdu Suncadia Medicine Co., Ltd., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangxi Shanxiang Pharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.

According to CRI's market research, from 2016 to 2019, Abiraterone's sales in the Chinese market have shown an upward trend. In 2017, the price of Abiraterone dropped and it was included in China's national medical insurance. Therefore, the sales of Abiraterone in the Chinese market increased the most significantly from 2017 to 2019. The annual sales revenue in 2019 is CNY566.84 million, which increased over 30 times compared to that in 2016. The outbreak of the COVID-19 epidemic in 2020 has impacted the overall diagnosis and treatment business of Chinese hospitals, so the sales value of Abiraterone in the Chinese market declined slightly in 2020. The CAGR of Abiraterone sales value in the Chinese market from 2016 to 2020 is 140.7%.

CRI analyzes that from 2021 to 2025, Abiraterone's sales in China will continue to grow as the improvement of COVID-19 epidemic. According to data from China National Cancer Registration Institute, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to rise, and its sales will also increase.

Topics Covered:

  • The impact of COVID-19 on China's Abiraterone market
  • Sales value of China's Abiraterone 2016-2020
  • Competitive landscape of China's Abiraterone market
  • Prices of Abiraterone in China
  • Prices of Abiraterone in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Abiraterone market
  • Prospect of China's Abiraterone market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Abiraterone

  • 1.1 Indications for Abiraterone
  • 1.2 Development of Abiraterone in China
  • 1.3 Governmental Approval of Abiraterone in China
  • 1.4 The Impact of COVID-19 on Abiraterone sales in China

2 Sales of Abiraterone in China, 2016-2020

  • 2.1 Sales Value of Abiraterone
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Abiraterone
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Abiraterone by Dosage Form in China, 2016-2020
    • 2.3.1 Tablet
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Abiraterone Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Abiraterone Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Janssen-Cilag International NV(BE)
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of ZYTIGA (Janssen-Cilag International NV(BE)'s Abiraterone) in China
  • 3.3 Chengdu Suncadia Medicine Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Aisente (Chengdu Suncadia Medicine Co., Ltd.'s Abiraterone) in China
  • 3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Qingkeshu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Abiraterone) in China
  • 3.5 Jiangxi Shanxiang Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Abiraterone (Jiangxi Shanxiang Pharmaceutical Co., Ltd.'s Abiraterone) in China
  • 3.6 Qilu Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Zhuorong (Qilu Pharmaceutical Co., Ltd.'s Abiraterone) in China

4 Prices of Abiraterone for Different Manufacturers in China, 2020-2021

  • 4.1 Janssen-Cilag International NV(BE) (ZYTIGA)
  • 4.2 Chengdu Suncadia Medicine Co., Ltd. (Aisente)
  • 4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(Qingkeshu)
  • 4.4 Jiangxi Shanxiang Pharmaceutical Co., Ltd.
  • 4.5 Qilu Pharmaceutical Co., Ltd.(Zhuorong)

5 Prospect of Chinese Abiraterone Market, 2021-2025

  • 5.1 Influential Factors of Chinese Abiraterone Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Abiraterone Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Abiraterone Tablet Registration in China
  • Chart Sales Value of Abiraterone Tablet over the World
  • Chart Sales Value of Abiraterone Tablet in China, 2016-2020
  • Chart Sales Value of Abiraterone Tablet in China by Regions, 2016-2020
  • Chart Sales Volume of Abiraterone Tablet in China, 2016-2020
  • Chart Sales Volume of Abiraterone Tablet in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Abiraterone Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of ZYTIGA in China, 2016-2020
  • Chart Sales Value and Volume of Aisente in China, 2016-2020
  • Chart Sales Value and Volume of Qingkeshu in China, 2016-2020
  • Chart Sales Value and Volume of Abiraterone in Jiangxi Shanxiang Pharmaceutical Co., Ltd. in China, 2016-2020
  • Chart Sales Value and Volume of Zhuorong in China, 2016-2020
  • Chart Referential Prices of ZYTIGA in China by Regions, 2020-2021
  • Chart Referential Prices of Aisente in China by Regions, 2020-2021
  • Chart Referential Prices of Qingkeshu in China by Regions, 2020-2021
  • Chart Referential Prices of Abiraterone in Jiangxi Shanxiang Pharmaceutical Co., Ltd. in China by Regions, 2020-2021
  • Chart Referential Prices of Zhuorong in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Abiraterone in China, 2021-2025
  • Chart Forecast on Sales Volume of Abiraterone in China, 2021-2025